Nanoparticular drug delivery system of cytarabine hydrochloride (CTH) for improved treatment of lymphoma

Journal of Biomedical Nanotechnology

Volumn 3, Issue 1, 2007, Pages 90-96

  Ruckmani, K ^a   Sivakumar, M ^a   Satheesh Kumar, S ^b  

^a BHARATHIDASAN UNIVERSITY   (India)

^b KAKATIYA UNIVERSITY   (India)

Author keywords

Cytarabine hydrochloride; Drug delivery; Eudragit; Lymphoma; Nanoparticles

Indexed keywords

CYTARABINE; EUDRAGIT; NANOPARTICLE; POLYMETHACRYLIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG STABILITY; DRUG STERILITY; EMULSION; IN VITRO STUDY; IN VIVO STUDY; LIFESPAN; LYMPHOMA; MALE; MEAN RESIDENCE TIME; MOUSE; NONHUMAN; PARTICLE SIZE; POLYMERIZATION; SINGLE DRUG DOSE; SUSTAINED DRUG RELEASE;

EID: 45849084283     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2007.016     Document Type: Conference Paper

References (22)

1. W. R. Vogler, Strategies in the treatment of acute myelogenous leukaemia. Leuk. Res. 16, 1141 (1992).
2. D. W. Kufe, Cytarabine (ara-C) in the treatment of preleukaemia. Current Hospital Topics, The Upjohn Company (1985), pp. 1-11.
3. J. Brosa, G. R. Whitmore, F. A. Valeriote, D. Collins, and W. R. Bruce, Studies on the persistence of methotrexate, cytosine arabinoside, and leucovorin in the serum of mice. J. Natl. Cancer Inst. 42, 235 ( 1969).
4. B. C. Baguley and E. M. Fakehaug, Plasma half-life of cytosine arabinoside (NSC - 63878) in patients treated for acute myeloblastic leukaemia. Cancer Chernother Rep. 55, 291 (1971).
5. M. G. Pallavicini, Cytosine arabinoside: Molecular, pharmacokinetic, and cytokinetic considerations. Pharmacol. Ther. 25, 207 (1984).
6. M. Karon and S. Shirakawa, The locus of action of 1β-D-arabino-furanosyl cytosine in the cell cycle. Cancer Res. 29, 687 (1969).
7. C. N. Coleman, R. G. Stoller, J. C. Drake, and B. A. Chabner, Deoxycytidine kinase: Properties of the enzyme from human leukaernic: granulocytes. Blood 46, 791 (1975).
8. K. F. R. Chowdary and A. Srinivasa Rao, Nanoparticles as drug carriers. Indian drugs 10, 549 (1997).
9. B. Roland and J. Siepman, Encyclopedia of Controlled Drug Delivery, edited by Edith Mathiowitx, John Wiley and Sons Inc., Canada (1999), pp. 664-689.
10. P. Whrle, B. Magneheim, and S. Benita, Influence of process parameters on the PLA nanoparticles: Size distribution evaluated by means of factorial design. Eur. J. Pharm. Biopharm. 4, 19 (1995).
11. M. Guzman, J. Molepeceres, F. Garcia, M. R. Aberturas, and M. Rodrìguez, Formation and characterisation of cyclosporine loaded nanoparticles. J. Pharm. Sci. 82, 498 (1993).
12. G. Cavallaro, M. Fresta, G. Giammona, G. Puglisi, and A. Villari, Entrapment of B-lactams antibiotics in polyethylcyanoacrylate nanoparticles studies on the possible in vivo application of this colloidal delivery. Int. J. Pharm. 111, 31 (1994).
13. I. Katuhiko, K. Tomohira, K. Kimo, I. Yasuhiko, and N. Nobao, Preparation of nanoparticles for cell targeting. Polym. J. 191, 283 (1991).
14. J. Fanny De, D. Eric, and G. Robert, Encyclopedia of Controlled Drug Delivery, edited by Edith Mathiowitx, John Wiley and Sons Inc., Canada (1999), pp. 641-663.
15. P. A. Maccarron and S. Keating, Optimization of poly(butyl cyanoacrylate) nanoparticulate: Size and polydispersity using central composite design. J. Pharm. Pharmacol. 50 (Supplement), 175 ( 1998).
16. H. Niwa, H. Takeuchi, T. Hino, N. Junnou, and Y. Kawashima, In vitro drug release behaviour of D.1 lactide/glycolide copolymer (PLGA) nanospheres with nafarelin acetate prepared by a novel spontaneous emulsification solvent diffusion method. J. Pharm. 83, 727(1994).
17. C. Gomez, M. D. Blanco, M. V. Bernardo, Sastre, and J. M. Teijon, Poly(acrylamide-co-monoethyl itaconate) hydrogels as devices for cytarabine release in rats. J. Pharm. Pharmacol. 50, 703 (1998).
18. J. C. White, J. P. Rathmell, and R. L. Capizzi, J. Clin. Invest. 79, 380(1987).
19. R. Capizzi, J. Courtland White, B. L. Powell, and E Perrino, Effect of dose and the pharmacokinetic and pharmacodynamic effects of cytarabine. Sermin. Haemotol. 28, 54 (1991).
20. G. M. Grass and J. R. Robinson, Sustained and Controlled Drug Delivery Systems, edited by G. S. Banker and C. T. Rhodes, Modem Pharmuaceutics, 2nd edn., Marcel Dekker Inc., New York (1990), pp. 635-671.
21. P. Couvreur, M. Roland, and P. Spencer, Biodegradable atkyl cyanoacrylate micellar polymers containing biologically active compounds and maybe administered parenterally to give prolonged release. Patent IP-0007895-A1 16.07.79.
22. L. G. Feninger and D. B. Midu, Advances in Cancer Research, Academic Press, New York (1954), p. 406.